- Home
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Club
- Mobile
- Trust Equitymaster
- Help
- Free Reports
-
Mobile App
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- SUN PHARMA - LUPIN LTD
SUN PHARMA vs LUPIN LTD - Comparison Results
SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
LUPIN LTD
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
Current Valuations
| SUN PHARMA | LUPIN LTD | SUN PHARMA/ LUPIN LTD |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 16.8 | 17.7 | 94.8% | View Chart |
| P/BV | x | 3.4 | 4.1 | 82.0% | View Chart |
| Dividend Yield | % | 0.7 | 0.7 | 91.0% |
Financials
 SUN PHARMA  LUPIN LTD |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-17 |
LUPIN LTD Mar-16 |
SUN PHARMA/ LUPIN LTD |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 842 | 2,127 | 39.6% | |
| Low | Rs | 572 | 1,294 | 44.2% | |
| Sales per share (Unadj.) | Rs | 131.6 | 304.1 | 43.3% | |
| Earnings per share (Unadj.) | Rs | 32.7 | 50.4 | 64.9% | |
| Cash flow per share (Unadj.) | Rs | 38.0 | 60.7 | 62.6% | |
| Dividends per share (Unadj.) | Rs | 3.50 | 7.50 | 46.7% | |
| Dividend yield (eoy) | % | 0.5 | 0.4 | 112.9% | |
| Book value per share (Unadj.) | Rs | 152.7 | 243.8 | 62.6% | |
| Shares outstanding (eoy) | m | 2,399.26 | 450.58 | 532.5% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 5.4 | 5.6 | 95.5% | |
| Avg P/E ratio | x | 21.6 | 33.9 | 63.7% | |
| P/CF ratio (eoy) | x | 18.6 | 28.2 | 66.1% | |
| Price / Book Value ratio | x | 4.6 | 7.0 | 66.0% | |
| Dividend payout | % | 10.7 | 14.9 | 71.9% | |
| Avg Mkt Cap | Rs m | 1,696,877 | 770,740 | 220.2% | |
| No. of employees | `000 | 17.5 | 16.4 | 107.1% | |
| Total wages/salary | Rs m | 49,023 | 21,077 | 232.6% | |
| Avg. sales/employee | Rs Th | 18,028.3 | 8,379.6 | 215.1% | |
| Avg. wages/employee | Rs Th | 2,798.8 | 1,289.0 | 217.1% | |
| Avg. net profit/employee | Rs Th | 4,479.5 | 1,388.7 | 322.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 315,784 | 137,016 | 230.5% | |
| Other income | Rs m | 6,232 | 1,877 | 332.0% | |
| Total revenues | Rs m | 322,016 | 138,893 | 231.8% | |
| Gross profit | Rs m | 100,893 | 37,535 | 268.8% | |
| Depreciation | Rs m | 12,648 | 4,635 | 272.9% | |
| Interest | Rs m | 3,998 | 446 | 896.0% | |
| Profit before tax | Rs m | 90,479 | 34,330 | 263.6% | |
| Minority Interest | Rs m | 0 | -88 | 0.0% | |
| Prior Period Items | Rs m | 99 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 12,116 | 11,536 | 105.0% | |
| Profit after tax | Rs m | 78,462 | 22,707 | 345.5% | |
| Gross profit margin | % | 31.9 | 27.4 | 116.6% | |
| Effective tax rate | % | 13.4 | 33.6 | 39.9% | |
| Net profit margin | % | 24.8 | 16.6 | 149.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 329,537 | 97,790 | 337.0% | |
| Current liabilities | Rs m | 178,870 | 53,872 | 332.0% | |
| Net working cap to sales | % | 47.7 | 32.1 | 148.9% | |
| Current ratio | x | 1.8 | 1.8 | 101.5% | |
| Inventory Days | Days | 79 | 85 | 93.3% | |
| Debtors Days | Days | 83 | 121 | 68.7% | |
| Net fixed assets | Rs m | 204,766 | 86,379 | 237.1% | |
| Share capital | Rs m | 2,399 | 901 | 266.2% | |
| "Free" reserves | Rs m | 363,997 | 105,735 | 344.3% | |
| Net worth | Rs m | 366,397 | 109,844 | 333.6% | |
| Long term debt | Rs m | 14,361 | 53,739 | 26.7% | |
| Total assets | Rs m | 614,102 | 224,378 | 273.7% | |
| Interest coverage | x | 23.6 | 77.9 | 30.3% | |
| Debt to equity ratio | x | 0 | 0.5 | 8.0% | |
| Sales to assets ratio | x | 0.5 | 0.6 | 84.2% | |
| Return on assets | % | 13.4 | 10.3 | 130.1% | |
| Return on equity | % | 21.4 | 20.7 | 103.6% | |
| Return on capital | % | 24.8 | 21.2 | 117.1% | |
| Exports to sales | % | 0 | 49.1 | 0.0% | |
| Imports to sales | % | 0 | 7.4 | 0.0% | |
| Exports (fob) | Rs m | NA | 67,244 | 0.0% | |
| Imports (cif) | Rs m | NA | 10,199 | 0.0% | |
| Fx inflow | Rs m | 44,118 | 71,405 | 61.8% | |
| Fx outflow | Rs m | 24,484 | 17,807 | 137.5% | |
| Net fx | Rs m | 19,634 | 53,598 | 36.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 70,822 | -3,690 | -1,919.5% | |
| From Investments | Rs m | -42,216 | -69,434 | 60.8% | |
| From Financial Activity | Rs m | -22,854 | 58,126 | -39.3% | |
| Net Cashflow | Rs m | 6,107 | -14,998 | -40.7% | |
Share Holding
| Indian Promoters | % | 63.7 | 46.6 | 136.7% | |
| Foreign collaborators | % | 0.0 | 0.2 | - | |
| Indian inst/Mut Fund | % | 5.1 | 11.3 | 45.4% | |
| FIIs | % | 23.0 | 31.9 | 72.1% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 8.3 | 10.1 | 82.2% | |
| Shareholders | 133,026 | 98,259 | 135.4% | ||
| Pledged promoter(s) holding | % | 0.5 | 0.0 | - |
Compare SUN PHARMA With: DISHMAN PHARMA ELDER PHARMA ALEMBIC LTD DR. DATSONS LABS CADILA HEALTHCARE
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Finishes on a Flat Note; Tata Stocks Rally(Closing)
Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement this week.
Related Views on News
Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)
Aug 14, 2017A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)
May 30, 2017US markets decline while other geographies grow in the quarter.
Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)
Aug 14, 2017GST impact coupled with price erosion in US leads to lower profits for the quarter.
Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)
May 29, 2017Currency fluctuation and one time provision impacts operating margins.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
More Views on NewsMost Popular
India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)
Sep 11, 2017The question is, whether real estate buyers are financial creditors or not.
Kim Jong Un Is Keeping Traders Busy(Daily Profit Hunter)
Sep 6, 2017You shouldn't worry about North Kore, War or Market Corrections.
180,000%: The Returns That Could Have Been(The 5 Minute Wrapup)
Sep 7, 2017For successful investing in small caps, it's important to know when not to press the panic button.
How To Link Aadhaar With Your Mutual Fund Investments(Outside View)
Sep 11, 2017The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.
Home Prices Chart a Steady Rise(Chart Of The Day)
Sep 7, 2017Home prices data throws up a positive surprise.
More|
| |
SUN PHARMA SHARE PRICE
Sep 19, 2017 03:36 PM
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 5-YR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
